Company Description
Amarin Corporation plc, a pharmaceutical company, engages in the development and commercialization of therapeutics for the treatment of cardiovascular diseases in the United States, Germany, Canada, Lebanon, and the United Arab Emirates.
Its lead product is VASCEPA, a prescription-only omega-3 fatty acid product, used as an adjunct to diet for reducing triglyceride levels in adult patients with severe hypertriglyceridemia.
The company sells its products principally to wholesalers and specialty pharmacy providers.
It has a collaboration with Mochida Pharmaceutical Co., Ltd. to develop and commercialize drug products and indications based on the active pharmaceutical ingredient in Vascepa, the omega-3 acid, and eicosapentaenoic acid.
The company was formerly known as Ethical Holdings plc and changed its name to Amarin Corporation plc in 1999.
Amarin Corporation plc was incorporated in 1989 and is headquartered in Dublin, Ireland.
| Country | IE |
| IPO Date | Apr 1, 1993 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 275 |
| CEO | Aaron D. Berg |
Contact Details
Address: Grand Canal Docklands Dublin, IE | |
| Website | https://www.amarincorp.com |
Stock Details
| Ticker Symbol | AMRN |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0000897448 |
| CUSIP Number | 023111206 |
| ISIN Number | US0231112063 |
| Employer ID | 00-0000000 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Aaron D. Berg | Chief Executive Officer, President & Director |
| Peter Fishman | Chief Financial Officer |
| Dr. David Keenan Ph.D. | Executive Vice President of Technical Operations & President of Europe |
| Dr. Nabil Abadir | Chief Medical Officer of Global Medical Affairs |
| Dr. Steven B. Ketchum Ph.D. | Executive Vice President, President of Research & Development and Chief Scientific Officer |
| Jonathan N. Provoost | Executive Vice President, Chief Legal & Compliance Officer and Secretary |
| Jordan Zwick | Senior Vice President of Corporate Business Development & Investor Relations |
| Laurent Abuaf | President of Europe & Senior Vice President |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Dec 18, 2024 | 8-K | Current Report |
| Nov 22, 2024 | 8-K | Current Report |
| Oct 31, 2024 | 3 | Filing |
| Oct 30, 2024 | 10-Q | Quarterly Report |
| Oct 30, 2024 | 8-K | Current Report |
| Oct 07, 2024 | 8-K | Current Report |
| Aug 05, 2024 | 4 | Filing |
| Aug 01, 2024 | 4 | Filing |
| Aug 01, 2024 | 4 | Filing |
| Jul 31, 2024 | 8-K | Current Report |